Obstructive sleep apnea (OSA) syndrome is a common disorder of repeated upper airway collapse during sleep, leading to recurrent hypoxia and hypercapnia [1]. Continuous positive airway pressure (CPAP) is the current gold standard care, but the adherence among patients varies between 60 and 70 % [1], and thus represents a major limitation in OSA treatment. Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications for type 2 diabetes mellitus (T2DM) and obesity, which are the main risk factors for OSA.
